cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Replimune Group Inc
2 own
1 watching
Current Price
$0
$-0.95
(-4.87%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,103.78M
52-Week High
52-Week High
29.5229
52-Week Low
52-Week Low
13.84
Average Volume
Average Volume
0.23M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,103.78M
icon52-Week High29.5229
icon52-Week Low13.84
iconAverage Volume0.23M
iconDividend Yield--
iconP/E Ratio--
What does the Replimune Group Inc do?
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. It is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More
How much money does Replimune Group Inc make?
News & Events about Replimune Group Inc.
Globe Newswire
26days ago
NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deelan PhD, as Forbions first Head of Impact & ESG. Silva has over 15 years of experience in ESG integration, sustainability ...
Globe Newswire
1month ago
Forbions largest fundraising to date750 million raised in the final close of the Forbion Ventures Fund VI 600 million raised in the final close of the Forbion Growth Opportunities Fund II Brings the total of funds under management at Forbion to 3 billion NAARDEN, The Netherlands and MUNICH, Germany...
Globe Newswire
2 months ago
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and...
Globe Newswire
3 months ago
Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline data from the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell ...
Globe Newswire
3 months ago
WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, ...
Frequently Asked Questions
Frequently Asked Questions
What is Replimune Group Inc share price today?
plus_minus_icon
Can Indians buy Replimune Group Inc shares?
plus_minus_icon
How can I buy Replimune Group Inc shares from India?
plus_minus_icon
Can Fractional shares of Replimune Group Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Replimune Group Inc stocks?
plus_minus_icon
What is today’s traded volume of Replimune Group Inc?
plus_minus_icon
What is today’s market capitalisation of Replimune Group Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Replimune Group Inc?
plus_minus_icon
What percentage is Replimune Group Inc down from its 52-Week High?
plus_minus_icon
What percentage is Replimune Group Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.95
(-4.87%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
INHIBRX INC
INHIBRX INC
$23.51
$-0.65 (-2.69 %)
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$22.05
$-0.05 (-0.23 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$13.67
$-0.40 (-2.84 %)
Cassava Sciences Inc
Cassava Sciences Inc
$22.80
$-0.77 (-3.27 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
INHIBRX INC
INHIBRX INC
$23.51
$-0.65 (-2.69 %)
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$22.05
$-0.05 (-0.23 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$13.67
$-0.40 (-2.84 %)
Cassava Sciences Inc
Cassava Sciences Inc
$22.80
$-0.77 (-3.27 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00